Biotech, cancer, VC
Intellikine, Chasing Hot Cancer Drug Target, Raises Big Venture Round
Luke Timmerman 7/2/09
La Jolla, CA-based Intellikine, a company developing drugs against one of the hottest targets in cancer biology, has nailed down $16 million in venture capital out of a round that could be worth as much as $38.5 million, according to a regulatory filing.
Intellikine got the capital infusion from its founding crew of investors—Sofinnova Ventures, Abingworth Management, and CMEA Ventures—as well as four new investors, says David Kabakoff, an executive in residence with Sofinnova in San Diego.
The company,... Read more »
Share
